title: Expression of phosphatidylserine-specific phospholipase A(1) mRNA in human THP-1-derived macrophages.
abstract: The expression of phosphatidylserine-specific phospholipase A(1) (PS-PLA(1)) is most upregulated in the genes of peripheral blood cells from chronic rejection model rats bearing long-term surviving cardiac allografts. The expression profile of PS-PLA(1) in peripheral blood cells responsible for the immune response may indicate a possible biological marker for rejection episodes. In this study, PS-PLA(1) mRNA expression was examined in human THP-1-derived macrophages. The effects of several immunosuppressive agents on this expression were also examined in in vitro experiments. A real-time RT-PCR analysis revealed that PS-PLA(1) mRNA expression was found in human THP-1-derived macrophages. This expression was enhanced in the cells stimulated with lipopolysaccharide (LPS), a toll-like receptor (TLR) 4 ligand. Other TLR ligands (TLR2, 3, 5, 7, and 9) did not show a significant induction of PS-PLA(1) mRNA. The time course of the mRNA expression profiles was different between PS-PLA(1) and tumor necrosis factor-α (TNF-α), which showed a maximal expression at 12 and 1 h after LPS stimulation, respectively. Among the observed immunosuppressive agents, corticosteroids, prednisolone, 6α-methylprednisolone, dexamethasone, and beclomethasone inhibited PS-PLA(1) expression with half-maximal inhibitory concentrations less than 3.0 nM, while methotrexate, cyclosporine A, tacrolimus, 6-mercaptopurine, and mycophenoic acid showed either a weak or moderate inhibition. These results suggest that the expression of PS-PLA(1) mRNA in THP-1-derived macrophages is activated via TLR4 and it is inhibited by corticosteroids, which are used at high dosages to suppress chronic allograft rejection.
authors.affiliation: Faculty of Pharmaceutical Sciences, Teikyo University, Kanagawa, Japan. hhosono@pharm.teikyo-u.ac.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hosono
authors.forename: Masato
authors.initials: M
authors.lastname: Homma
authors.forename: Yoko
authors.initials: Y
authors.lastname: Ogasawara
authors.forename: Kumiko
authors.initials: K
authors.lastname: Makide
authors.forename: Junken
authors.initials: J
authors.lastname: Aoki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Niwata
authors.forename: Machiko
authors.initials: M
authors.lastname: Watanabe
authors.forename: Keizo
authors.initials: K
authors.lastname: Inoue
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Ohkohchi
authors.forename: Yukinao
authors.initials: Y
authors.lastname: Kohda
mesh_terms: D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000201:enzymology*; D054466:Phospholipases A1 / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D008070:Lipopolysaccharides; D012333:RNA, Messenger; C512665:PLA1A protein, human; D054466:Phospholipases A1